UTHR
UNITED THERAPEUTICS Corp
NASDAQ · Healthcare · Biotechnology · US
$494.63
−0.53%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $6.47
- Revenue estimate
- $791.0M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $7.27
- EPS estimate
- $6.86
- Revenue actual
- $783.3M
- Revenue estimate
- $806.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +1.5%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $659
- PT range
- $613 – $687
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $6.86 | $7.27 | Beat 5.96% | $783.3M |
| May 6, 2026 | $7.01 | $5.82 | Miss -16.98% | $781.5M |
| Feb 25, 2026 | $6.79 | $7.70 | Beat 13.44% | $790.2M |
| Oct 29, 2025 | $6.90 | $7.16 | Beat 3.72% | $799.5M |
| Jul 30, 2025 | $7.28 | $6.41 | Miss -11.99% | $798.6M |
| Apr 30, 2025 | $6.32 | $6.63 | Beat 4.95% | $794.4M |
| Feb 26, 2025 | $6.38 | $6.19 | Miss -2.99% | $735.9M |
| Oct 30, 2024 | $6.43 | $6.39 | Miss -0.68% | $748.9M |
| Jul 31, 2024 | $6.42 | $5.85 | Miss -8.89% | $714.9M |
| May 1, 2024 | $5.67 | $6.17 | Beat 8.91% | $677.7M |
| Feb 21, 2024 | $4.17 | $4.36 | Beat 4.51% | $614.7M |
| Nov 1, 2023 | $5.07 | $5.38 | Beat 6.09% | $609.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026